These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 18636187

  • 1. Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma.
    Ohtaka K, Kohya N, Sato K, Kitajima Y, Ide T, Mitsuno M, Miyazaki K.
    Oncol Rep; 2008 Aug; 20(2):279-86. PubMed ID: 18636187
    [Abstract] [Full Text] [Related]

  • 2. Ribonucleotide reductase subunit M1 assessed by quantitative double-fluorescence immunohistochemistry predicts the efficacy of gemcitabine in biliary tract carcinoma.
    Nakamura J, Kohya N, Kai K, Ohtaka K, Hashiguchi K, Hiraki M, Kitajima Y, Tokunaga O, Noshiro H, Miyazaki K.
    Int J Oncol; 2010 Oct; 37(4):845-52. PubMed ID: 20811706
    [Abstract] [Full Text] [Related]

  • 3. Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells.
    Tokunaga Y, Liu D, Nakano J, Zhang X, Nii K, Go T, Huang CL, Yokomise H.
    Eur J Cancer; 2015 Nov; 51(16):2480-9. PubMed ID: 26254808
    [Abstract] [Full Text] [Related]

  • 4. [Relationship between the level of RRM1 expression and the sensitivity to gemcitabine in the esophageal squamous cell carcinoma cell lines].
    Luo Y, Lin C, Zhang XY, Liang X, Fu M, Feng FY.
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):660-3. PubMed ID: 20021860
    [Abstract] [Full Text] [Related]

  • 5. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer.
    Nakahira S, Nakamori S, Tsujie M, Takahashi Y, Okami J, Yoshioka S, Yamasaki M, Marubashi S, Takemasa I, Miyamoto A, Takeda Y, Nagano H, Dono K, Umeshita K, Sakon M, Monden M.
    Int J Cancer; 2007 Mar 15; 120(6):1355-63. PubMed ID: 17131328
    [Abstract] [Full Text] [Related]

  • 6. Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone.
    Murata A, Amano R, Yamada N, Kimura K, Yashiro M, Nakata B, Hirakawa K.
    World J Surg Oncol; 2013 May 27; 11():117. PubMed ID: 23710668
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene.
    Kim SO, Jeong JY, Kim MR, Cho HJ, Ju JY, Kwon YS, Oh IJ, Kim KS, Kim YI, Lim SC, Kim YC.
    Clin Cancer Res; 2008 May 15; 14(10):3083-8. PubMed ID: 18483375
    [Abstract] [Full Text] [Related]

  • 9. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
    Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, Yu J, Kayashima T, Souzaki R, Tajiri T, Manabe T, Ohtsuka T, Tanaka M.
    Neoplasia; 2010 Oct 15; 12(10):807-17. PubMed ID: 20927319
    [Abstract] [Full Text] [Related]

  • 10. Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells.
    Zhang X, Taoka R, Liu D, Matsuoka Y, Tohi Y, Kakehi Y, Sugimoto M.
    Int J Mol Sci; 2021 Apr 15; 22(8):. PubMed ID: 33921102
    [Abstract] [Full Text] [Related]

  • 11. Tranilast strongly sensitizes pancreatic cancer cells to gemcitabine via decreasing protein expression of ribonucleotide reductase 1.
    Mitsuno M, Kitajima Y, Ohtaka K, Kai K, Hashiguchi K, Nakamura J, Hiraki M, Noshiro H, Miyazaki K.
    Int J Oncol; 2010 Feb 15; 36(2):341-9. PubMed ID: 20043067
    [Abstract] [Full Text] [Related]

  • 12. MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer.
    Fan P, Liu L, Yin Y, Zhao Z, Zhang Y, Amponsah PS, Xiao X, Bauer N, Abukiwan A, Nwaeburu CC, Gladkich J, Gao C, Schemmer P, Gross W, Herr I.
    Cancer Lett; 2016 Apr 01; 373(1):130-137. PubMed ID: 26828016
    [Abstract] [Full Text] [Related]

  • 13. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.
    Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA.
    Cancer Res; 2004 Jun 01; 64(11):3761-6. PubMed ID: 15172981
    [Abstract] [Full Text] [Related]

  • 14. MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.
    Rajabpour A, Afgar A, Mahmoodzadeh H, Radfar JE, Rajaei F, Teimoori-Toolabi L.
    Cancer Chemother Pharmacol; 2017 Oct 01; 80(4):765-775. PubMed ID: 28887583
    [Abstract] [Full Text] [Related]

  • 15. Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.
    Kwon WS, Rha SY, Choi YH, Lee JO, Park KH, Jung JJ, Kim TS, Jeung HC, Chung HC.
    Pharmacogenet Genomics; 2006 Jun 01; 16(6):429-38. PubMed ID: 16708051
    [Abstract] [Full Text] [Related]

  • 16. Identification of chemoresistance-related mRNAs based on gemcitabine-resistant pancreatic cancer cell lines.
    Zhou J, Zhang L, Zheng H, Ge W, Huang Y, Yan Y, Zhou X, Zhu W, Kong Y, Ding Y, Wang W.
    Cancer Med; 2020 Feb 01; 9(3):1115-1130. PubMed ID: 31823522
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
    Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, Provencio M, Isla D, Taron M, Diz P, Artal A, Spanish Lung Cancer Group.
    Clin Cancer Res; 2004 Feb 15; 10(4):1318-25. PubMed ID: 14977831
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy.
    Sasaki H, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Sueda T.
    Br J Cancer; 2014 Sep 23; 111(7):1275-84. PubMed ID: 25032731
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.